

On Page 22, line 30 please rewrite "fulfamoyl group" to read --sulfamoyl group--

On Page 22, line 31 please rewrite "fulfamoyl group" to read --sulfamoyl group--

On Page 22, line 33 please rewrite "fulfamoyl group" to read --sulfamoyl group--

On Page 89. lines 27-29 please rewrite

"... a cyclic aminosulfonyl group selected from Group 20, a C<sub>1-6</sub> alkylsulfonyl group or a C<sub>3-6</sub> cycloalkyl sulfonyl group..."

to read:

--... (iv) a cyclic aminosulfonyl group selected from Group 20, (v) a C<sub>1-6</sub> alkylsulfonyl group or (vi) a C<sub>3-6</sub> cycloalkyl sulfonyl group...--

#### REMARKS

The specification is amended above to insert a reference to related cases.

The requested amendments correct typographical errors.

No amendment of inventorship is necessitated by these amendments.

Early allowance of the claims is requested. Should the Examiner believe that a conference with applicants' attorney would advance prosecution of this application, the Examiner is respectfully invited to call applicants' attorney.

Respectfully submitted,



Dated: April 4, 2002

(847)383-3372

(847)383-3391

Mark Chao, Ph.D., Reg. No. 37,293

Elaine M. Ramesh, Ph.D., Reg. No. 43032

Attorney for Applicants

Customer No. 23115

Takeda Pharmaceuticals North America, Inc.  
Intellectual Property Department  
Suite 500, 475 Half Day Road  
Lincolnshire, IL 60069 USA